Journal
JOURNAL OF INTENSIVE CARE
Volume 2, Issue -, Pages -Publisher
BMC
DOI: 10.1186/2052-0492-2-20
Keywords
Disseminated intravascular coagulation; DIC with suppressed fibrinolysis; DIC with enhanced fibrinolysis; DIC with balanced fibrinolysis; Tranexamic acid
Categories
Funding
- Grants-in-Aid for Scientific Research [25462818] Funding Source: KAKEN
Ask authors/readers for more resources
Disseminated intravascular coagulation (DIC) has a common pathogenesis in terms of persistent widespread activation of coagulation in the presence of underlying disease, but the degree of fibrinolytic activation often differs by DIC type. DIC with suppressed fibrinolysis is a DIC type usually seen in sepsis. Coagulation activation is severe, but fibrinolytic activation is mild. DIC with enhanced fibrinolysis is a DIC type usually seen in acute promyelocytic leukemia (APL). Both coagulation activation and fibrinolytic activation are severe. DIC with balanced fibrinolysis is a DIC type usually seen in solid tumors, with an intermediate pathogenesis between the above two types. In animal DIC models, lipopolysaccharide (LPS)-induced models are similar to suppressed-fibrinolytic-type DIC, whereas tissue factor (TF)-induced models are similar to enhanced fibrinolytic/balanced fibrinolytic DIC. Appropriate diagnosis and treatment may also differ depending on the DIC type.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available